DRK Kliniken Berlin
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At DRK Kliniken Berlin, clinical research in cardiovascular medicine focuses on reducing major heart and vascular events in people at elevated risk. The studies are designed to assess whether new treatments can better prevent serious outcomes such as heart attack, stroke, and other atherosclerotic cardiovascular disease complications.
- Reducing the risk of major adverse cardiovascular events in high-risk patients
- Evaluating new options for coronary heart disease prevention
- Testing treatments aimed at improving long-term cardiovascular safety
These trials reflect a strong interest in finding more effective ways to prevent serious cardiovascular events and improve outcomes for people with obesity-related or heart-disease-related risk factors.
Neoplasms
The site also supports research in oncology, with a particular focus on breast cancer and metastatic colorectal cancer. The studies are exploring whether newer treatment approaches can improve cancer control and help prevent recurrence in patients with early-stage or advanced disease.
- Studying treatment strategies for ER+/HER2- early breast cancer
- Evaluating new approaches for metastatic colorectal cancer
- Assessing whether emerging therapies can improve cancer recurrence prevention
This research highlights the role of Brustzentrum in advancing cancer care through trials that compare new therapies with established treatment standards.
Nutritional and Metabolic Diseases
Clinical trials in nutritional and metabolic diseases at this Berlin site are centered on obesity and related health risks. The research is examining whether new therapies can support better weight-related disease management while also lowering the chance of downstream cardiovascular complications.
- Investigating treatments for obesity and related metabolic risk
- Exploring links between weight management and cardiovascular health
- Testing therapies intended to improve long-term disease prevention
These studies show a broad interest in conditions where metabolism, weight, and heart health overlap, with the goal of improving everyday care for patients at risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1Merck Sharp & Dohme LLC2active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC4trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in DRK Kliniken Berlin
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sotatercept | 5 | Unknown | 2021-08-26 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.